Fig 1: PAX2 promotes fatty acid metabolism reprogramming in RM tumors and ovarian cancer tissues. (A) Western blot analysis of the expression of PAX2, FABP4 and LIPA in RM-WPI or RM-PAX2 tumor tissue, contralateral ovarian and fallopian tube tissues, and from a case of human serous ovarian cancer. SKOV3 and T24 cell lines were used as negative controls for PAX2 expression. (B) Western blot analysis of the expression of PAX2, FABP4 and LIPA in cancer tissues from PAX2 strong (PAX2+++) or weak (PAX2+) serous ovarian cancer patients. Non-cancerous contralateral ovarian and fallopian tube tissues were also analyzed. GAPDH was used as a loading control. Images are representative of 3 replicate experiments. PAX2 and FABP4 were probed from the same membrane, LIPA was probed from another membrane. (C) Western blot analysis of the expression of PAX2, PNLIP and ACAA2 in cancer tissues from an additional six serous ovarian cancer patients. PAX2 and ACAA2 were probed from the same membrane, PNLIP was probed from membrane. PAX2, paired box 2.
Fig 2: ACAA2 overexpression is associated with a poor prognosis of patients with ovarian cancer. (A and B) Kaplan-Meier progression-free survival curves for patients with a low or high expression of (A) ACAA2 or (B) PNLIP among the total number of patients; (C-E) Kaplan-Meier progression-free survival curves for patients with (C) a negative PAX2 expression (PAX2-) or positive PAX2 expression (PAX2+), (D) low or high ACAA2 expression or (E) low or high PNLIP in expression RAS positive (RAS+) subgroup.
Supplier Page from Abcam for Anti-Pancreatic Lipase/PTL antibody